EP1410796A3 - Nouvelles applications thérapeutiques des activateurs des canaux potassiques - Google Patents

Nouvelles applications thérapeutiques des activateurs des canaux potassiques Download PDF

Info

Publication number: EP1410796A3
Authority: EP; European Patent Office
Prior art keywords: potassium channel; channel openers; therapeutic uses; new therapeutic; openers
Prior art date: 1999-07-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP03078617A

Other languages

German (de)

English (en)

Other versions

EP1410796A2 (fr

Inventor

Stephen Anthony Burbidge, (GlaxoSmithKline

Jeffrey John GlaxoSmithkline Clare

Brian GlaxoSmithKline COX

Joseph Dupere

Russell Michael SmithKline Becham Corp. Hagan

Xinmin Xie

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-01

Filing date

2000-06-30

Publication date

2004-07-14

2000-06-30 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-04-21 Publication of EP1410796A2 publication Critical patent/EP1410796A2/fr

2004-07-14 Publication of EP1410796A3 publication Critical patent/EP1410796A3/fr

Status Withdrawn legal-status Critical Current

Links

229940127315 Potassium Channel Openers Drugs 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
108010006746 KCNQ2 Potassium Channel Proteins 0.000 abstract 1
102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 abstract 1
PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 abstract 1
229960003312 retigabine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP03078617A 1999-07-01 2000-06-30 Nouvelles applications thérapeutiques des activateurs des canaux potassiques Withdrawn EP1410796A3 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9915414.8A GB9915414D0 (en)	1999-07-01	1999-07-01	Medical use
GB9915414		1999-07-01
EP00940669A EP1207863A2 (fr)	1999-07-01	2000-06-30	Nouvelles utilisations des agents d'ouverture du canal potassique

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00940669A Division EP1207863A2 (fr)	1999-07-01	2000-06-30	Nouvelles utilisations des agents d'ouverture du canal potassique

Publications (2)

Publication Number	Publication Date
EP1410796A2 EP1410796A2 (fr)	2004-04-21
EP1410796A3 true EP1410796A3 (fr)	2004-07-14

Family

ID=10856438

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP03078618A Withdrawn EP1407768A3 (fr)	1999-07-01	2000-06-30	L'agoniste des canaux potassiques retigabine pour le traitement de maladies
EP00940669A Withdrawn EP1207863A2 (fr)	1999-07-01	2000-06-30	Nouvelles utilisations des agents d'ouverture du canal potassique
EP03078617A Withdrawn EP1410796A3 (fr)	1999-07-01	2000-06-30	Nouvelles applications thérapeutiques des activateurs des canaux potassiques

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP03078618A Withdrawn EP1407768A3 (fr)	1999-07-01	2000-06-30	L'agoniste des canaux potassiques retigabine pour le traitement de maladies
EP00940669A Withdrawn EP1207863A2 (fr)	1999-07-01	2000-06-30	Nouvelles utilisations des agents d'ouverture du canal potassique

Country Status (5)

Country	Link
EP (3)	EP1407768A3 (fr)
JP (1)	JP2003503447A (fr)
AU (1)	AU5557700A (fr)
GB (1)	GB9915414D0 (fr)
WO (1)	WO2001001970A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6472165B1 (en)	1999-08-03	2002-10-29	Arzneimittelwerk Dresden Gmbh	Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) *	1999-09-27	2000-09-12	Asta Medica Aktiengesellschaft	Use of retigabine for the treatment of neuropathic pain
AU2001265840A1 (en) *	2000-06-26	2002-01-08	Novo-Nordisk A/S	Use of potassium channel agonists for reducing fat food comsumption
DE10048969A1 (de) *	2000-08-23	2002-03-14	Mueller Schwefe Gerhard	Verwendung von Flupirtin zur Tinnitusbehandlung
US6348486B1 (en)	2000-10-17	2002-02-19	American Home Products Corporation	Methods for modulating bladder function
US6589986B2 (en) *	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders
US20020183395A1 (en)	2001-04-04	2002-12-05	Wyeth	Methods for treating hyperactive gastric motility
ES2282701T3 (es) *	2002-12-27	2007-10-16	H. Lundbeck A/S	Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
CN100448867C (zh) *	2002-12-27	2009-01-07	H·隆德贝克有限公司	用于治疗中枢神经系统疾病的1,2,4-三氨基苯衍生物
MXPA05010174A (es) *	2003-04-25	2005-11-08	Lundbeck & Co As H	Derivados de indol e indolina sustituidos.
US20050089559A1 (en) *	2003-10-23	2005-04-28	Istvan Szelenyi	Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
EP1828413A1 (fr) *	2004-12-24	2007-09-05	Ares Trading S.A.	Compositions et méthodes pour le traitement de désordres mentaux
TWI453013B (zh) *	2006-02-07	2014-09-21	Lundbeck & Co As H	N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
WO2007128462A1 (fr) *	2006-05-02	2007-11-15	Chris Rundfeldt	Activateurs de canaux potassiques pour la prévention et le traitement de la dystonie et des systèmes assimilés à la dystonie
US7960436B2 (en)	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en)	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en)	2006-08-23	2011-09-29	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en)	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh)	2006-11-28	2009-11-11	威朗国际制药公司	作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en)	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
AR070513A1 (es) *	2007-08-01	2010-04-14	Lundbeck & Co As H	Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
US7786146B2 (en)	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2300044A4 (fr) *	2008-05-06	2012-04-18	Relevare Aust Pty Ltd	Procédés et compositions pour la prise en charge de la douleur à base d' oméga-conotoxines
US9326955B2 (en) *	2008-10-31	2016-05-03	Loyola University Chicago	Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
DE102009013612A1 (de) *	2009-03-17	2010-09-23	Ratiopharm Gmbh	Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
CN104470893A (zh) *	2012-04-30	2015-03-25	赛弗卢尔生命科学有限责任公司	氟化2-氨基-4-(苄基氨基)苯基氨基甲酸酯衍生物
MX2018015251A (es)	2016-06-10	2019-04-25	Scifluor Life Sciences Inc	Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
WO2019014547A1 (fr) *	2017-07-14	2019-01-17	Texas Tech University System	Carbamates de pyridine fonctionnalisés présentant une activité neuroprotectrice améliorée
WO2019118657A1 (fr)	2017-12-13	2019-06-20	Scifluor Life Sciences, Inc.	Dérivés fluorés 4-(amino substitué)phényl carbamate
US11358930B2 (en)	2018-04-20	2022-06-14	University of Pittsburgh—of the Commonwealth System of Higher Education	Selective potassium channel agonists
US12268683B2 (en)	2018-07-18	2025-04-08	The Regents Of The University Of California	Compounds and methods for synergistic activation of M channels
CN114206328B (zh)	2019-08-02	2024-09-17	H.隆德贝克有限公司	用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
MX2022005490A (es)	2019-11-08	2022-08-10	Xenon Pharmaceuticals Inc	Metodos para el tratamiento de trastornos depresivos.
CN114786658A (zh) *	2019-12-06	2022-07-22	泽农医药公司	Kv7钾离子通道开放剂治疗疼痛的用途
US11957675B2 (en)	2021-02-09	2024-04-16	Xenon Pharmaceuticals Inc.	Methods and uses for treating anhedonia
GB202306914D0 (en) *	2023-05-10	2023-06-21	Sania Rx Ltd	Method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5384330A (en) *	1992-01-08	1995-01-24	Asta Medica Aktiengesellschaft	Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them
WO1999021875A1 (fr) *	1997-10-24	1999-05-06	University Of Utah Research Foundation	Kncq2 et kncq3, genes du canal potassium ayant subi une mutation dans des convulsions neonatales familiales benignes (bfnc) et d'autres epilepsies
WO1999031232A1 (fr) *	1997-12-13	1999-06-24	Astrazeneka Uk Limited	Canal potassique kcnq2 extrait du cerveau humain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989010757A1 (fr) *	1988-05-10	1989-11-16	Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis	Nouvelle preparation ophtalmique pour le traitement de glaucomes
DE19539861A1 (de) *	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
TW467902B (en) *	1996-07-31	2001-12-11	Bristol Myers Squibb Co	Diphenyl heterocycles as potassium channel modulators
TW504504B (en) *	1996-11-26	2002-10-01	Bristol Myers Squibb Co	4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators

1999
- 1999-07-01 GB GBGB9915414.8A patent/GB9915414D0/en not_active Ceased
2000
- 2000-06-30 AU AU55577/00A patent/AU5557700A/en not_active Abandoned
- 2000-06-30 WO PCT/GB2000/002516 patent/WO2001001970A2/fr not_active Ceased
- 2000-06-30 EP EP03078618A patent/EP1407768A3/fr not_active Withdrawn
- 2000-06-30 JP JP2001507464A patent/JP2003503447A/ja active Pending
- 2000-06-30 EP EP00940669A patent/EP1207863A2/fr not_active Withdrawn
- 2000-06-30 EP EP03078617A patent/EP1410796A3/fr not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5384330A (en) *	1992-01-08	1995-01-24	Asta Medica Aktiengesellschaft	Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them
WO1999021875A1 (fr) *	1997-10-24	1999-05-06	University Of Utah Research Foundation	Kncq2 et kncq3, genes du canal potassium ayant subi une mutation dans des convulsions neonatales familiales benignes (bfnc) et d'autres epilepsies
WO1999031232A1 (fr) *	1997-12-13	1999-06-24	Astrazeneka Uk Limited	Canal potassique kcnq2 extrait du cerveau humain

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIALER M. ET AL: "Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference.", EPILEPSY RESEARCH, (1996) 25/3 (299-319)., XP002107785 *
BUXTON A ET AL: "CHOLINERGIC AGENTS AND DELAY-DEPENDENT PERFORMANCE IN THE RAT", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 49, no. 4, December 1994 (1994-12-01), pages 1067 - 1073, XP000884719, ISSN: 0091-3057 *
DOST R. ET AL: "The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation.", EPILEPSY RESEARCH, (1999) 38/1 (53-66)., XP001012551 *
KAPETANOVIC I.M. ET AL: "D - 23129: A new anticonvulsant compound.", CNS DRUG REVIEWS, (1996) 2/3 (308-321)., XP001014121 *
RUNDFELDT C (REPRINT) ET AL: "The anticonvulsant drug retigabine is effective on 4-aminopyridine induced epileptiform activity in vitro", EUROPEAN JOURNAL OF NEUROSCIENCE, (AUG 1998) VOL. 10, SUPP. [10], PP. 2028-2028. PUBLISHER: BLACKWELL SCIENCE LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND. ISSN: 0953-816X., ARZNEIMITTELWERK DRESDEN, DEPT PHARMACOL 1, CORP R&D ASTA MED GRP, D-0144 RADEBEUL, GERMANY;CHARITE BERLIN, DEPT NEUROPHYSIOL, D-10117 BERLIN, GERMANY, XP001014127 *
RUNDFELDT C.: "Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.", EPILEPSY RESEARCH, (1999) 35/2 (99-107)., XP000972218 *
RUNDFELDT CHRIS ET AL: "The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.", NEUROSCIENCE LETTERS, vol. 282, no. 1-2, 17 March 2000 (2000-03-17), pages 73 - 76, XP000972246, ISSN: 0304-3940 *
STEIN V (REPRINT) ET AL: "Moderate loss of function of cAMP- modulated KCNQ2 KCNQ3 K+ channels is sufficient to cause epilepsy", JOURNAL OF NEUROCHEMISTRY, (JUL 1999) VOL. 73, SUPP. [S], PP. S128-S128. PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106. ISSN: 0022-3042., XP001014124 *
TINEL NORBERT ET AL: "The KCNQ2 potassium channel: Splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3.", FEBS LETTERS, vol. 438, no. 3, 6 November 1998 (1998-11-06), pages 171 - 176, XP004258585, ISSN: 0014-5793 *
TOBER C. ET AL: "D - 23129.", DRUGS OF THE FUTURE, (1995) 20/11 (1112-1115)., XP001014125 *

Also Published As

Publication number	Publication date
WO2001001970A2 (fr)	2001-01-11
EP1407768A2 (fr)	2004-04-14
EP1207863A2 (fr)	2002-05-29
AU5557700A (en)	2001-01-22
GB9915414D0 (en)	1999-09-01
EP1410796A2 (fr)	2004-04-21
EP1407768A3 (fr)	2004-04-21
WO2001001970A3 (fr)	2002-02-28
JP2003503447A (ja)	2003-01-28

Legal Events

Date	Code	Title	Description
2004-03-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-04-21	17P	Request for examination filed	Effective date: 20031113
2004-04-21	AC	Divisional application: reference to earlier application	Ref document number: 1207863 Country of ref document: EP Kind code of ref document: P
2004-04-21	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-05-28	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2004-07-14	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2005-04-06	AKX	Designation fees paid	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2005-06-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2005-07-27	18D	Application deemed to be withdrawn	Effective date: 20050115

Publication	Publication Date	Title
EP1410796A3 (fr)	2004-07-14	Nouvelles applications thérapeutiques des activateurs des canaux potassiques
AU2561799A (en)	1999-09-15	Radiotelephone adapted to the identity of its user
WO2001010380A3 (fr)	2001-08-16	Benzanilides comme ouvreurs de canaux potassiques
PL372944A1 (en)	2005-08-08	2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
AU5787799A (en)	2000-03-27	Facial iron
ZA9710098B (en)	1998-05-25	Halogenopyrimidines.
AU2001249423A1 (en)	2001-10-08	38692 and 21117, novel dual specificity phosphatase molecules and uses therefor
AU1378500A (en)	2000-05-29	Novel pyrimidines, the production thereof and their use
MXPA01008188A (es)	2003-07-21	Procesos e intermediarios para la preparacion de 1,3-oxazin-6-onas y uracilos.
ZA9811591B (en)	1999-06-17	Potassium channel openers
WO1999007729A3 (fr)	1999-06-03	Peptides exerçant une activite d'ouverture des canaux de potassium
AU3896899A (en)	1999-11-29	Compositions for the treatment of tumors, and uses thereof
AU1651001A (en)	2001-06-18	Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof
WO2004016640A3 (fr)	2004-07-08	Intermediaires de 5 androstene-3?-ol steroides et leurs procedes de preparation
AU2002338572A1 (en)	2002-11-11	66784, a novel human potassium channel and uses therefor
AU2001265841A1 (en)	2002-01-08	Use of potassium channel openers for the treatment of insulitis
AU2001265384A1 (en)	2001-12-17	52906, 33408, and 12189, potassium channel family members and uses thereof
AU2717399A (en)	1999-08-02	Two p domains potassium channel
AU1356701A (en)	2001-05-14	Novel potassium channel molecules and uses therefor
AU5122700A (en)	2000-11-14	Channel forming toxins as antiviral agents
AU2532299A (en)	1999-08-30	Potassium channel polypeptide
AU2001296780A1 (en)	2002-04-15	48120, 23479, and 46689, novel human hydrolases and uses thereof
AU2001273452A1 (en)	2002-01-30	47885, a novel human ubiquitin-activating enzyme and uses therefor
AU3835499A (en)	1999-11-29	Potassium channel subunit
ZA200002987B (en)	2001-12-14	Novel processes and intermediates.